“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A study looking at blood vessel cells in the bloodstreams of women having chemotherapy for ovarian, primary peritoneal or fallopian tube cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This study looked at cells that have broken away from
- ovarian cancer
- primary peritoneal cancer
- fallopian tube cancer
More about this trial
New drugs (anti angiogenics) are being developed that will block this process. But they don’t work for everyone. At the moment the only way doctors can tell if these drugs are working is by looking at a CT scan after you’ve had treatment. They need to develop other tests that show if anti angiogenics are working earlier than this.
A way to do this may be by looking at damaged blood vessel lining cells that are released into the bloodstream. These lining cells are called endothelial cells, so those in the bloodstream are called circulating endothelial cells (CECs).
Researchers have found that increased numbers of CECs in people with cancer may be a sign (biomarker) that new blood vessels are being formed. If the number of CECs drops during treatment, it could show that anti angiogenic treatment is working.
Researchers wanted to measure this when people were having a chemotherapy called paclitaxel. Paclitaxel blocks blood vessel growth. They wanted to look at the effect of paclitaxel chemotherapy on the number of CECs.
If they could see that paclitaxel reduces the number of CECs, this could also be a way of measuring how well other anti angiogenic drugs are working in future.
They will also wanted to look for other related
Summary of results
The researchers were unable to get enough people to take part. So there will be no results for this study.
How to join a clinical trial
Professor Gordon Jayson
Experimental Cancer Medicine Centre (ECMC)
The Christie NHS Foundation Trust